Sino Biopharmaceutical Limited (SBHMY) Stock Price & Analysis
Sino Biopharmaceutical Limited (SBHMY) — price $14.40 (0.00%), as of the Nov 19, 2026 trading session; market cap $12.8B.
Educational signal · not a buy or sell recommendation · How to read this
Sino Biopharmaceutical Limited · SBHMY · Healthcare · Medical - Pharmaceuticals
Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $14.40 | |
| Change on the day | 0.00% | |
| 52-week range | $11.27–$19.45 | |
| Market capitalisation | $12.8B | — |
| Price / earnings (trailing) | 34.19 | |
| Shares traded on the day | 200 | |
| Beta (volatility vs the S&P 500) | 0.61 | |
| Dividends per share (last 12 months) | $0.31 | |
| Dividend yield (last 12 months) | 2.13% |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Sino Biopharmaceutical (SBHMY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Sino Biopharmaceutical (SBHMY), and what does it report?
Short answer
Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. Healthcare / Medical Pharmaceuticals Headquarters: Unit 09, Office Tower, Hong Kong, HK. It employs 21,435 people and is led by S. Y. Tse. In Q2 FY2026 it reported revenue of CN¥9.72B and net income of CN¥1.72B. The market values it at $12.8B.
What do the latest results show for Sino Biopharmaceutical (SBHMY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CN¥9.72B.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.23B Aug 15, 2025
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 15, 2025 | $1.23B | Not available | $0.2621 | Not available |
| Mar 26, 2025 | $889.68M | Not available | $0.0018 | Not available |
| Mar 20, 2025 | $925.73M | Not available | $0.0019 | Not available |
| Aug 13, 2024 | $1.09B | Not available | $0.0113 | Not available |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CN¥9.72B | CN¥1.72B | CN¥1.90 (diluted) |
| Q1 FY2026 | CN¥9.72B | CN¥1.72B | CN¥1.90 (diluted) |
| Q4 FY2025 | CN¥7.13B | -CN¥523M | -CN¥0.58 (diluted) |
| Q3 FY2025 | CN¥7.13B | -CN¥523M | -CN¥0.58 (diluted) |
What are the financial strengths and risks for Sino Biopharmaceutical (SBHMY)?
Short answer · as of
The distress and quality screens read Altman Z 2.86 · Piotroski F 6. Trailing ratios: ROE 7.6% · ROA 2.9% · current ratio 1.63 · earnings yield 2.8% · free-cash-flow yield 6.2%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SBHMY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SBHMY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Sino Biopharmaceutical (SBHMY) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do Qingkeshu and Leweixin fit Sino Biopharmaceutical’s business?
Qingkeshu tablets and Leweixin injections are oncology products within a much broader medicine portfolio. Their presence illustrates the group’s therapeutic breadth rather than defining Sino Biopharmaceutical as an oncology-only company.
What is the SBHMY stock price today?
The last price recorded for Sino Biopharmaceutical Limited (SBHMY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does SBHMY pay a dividend?
Yes. The dividend yield of Sino Biopharmaceutical Limited (SBHMY) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 29 figures on this page — 24 from Financial Modeling Prep (FMP), 3 with no recorded source and 2 computed by us, formula shown in the register. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com